Rocket Pharmaceuticals Inc

RCKT

Add to Watchlist

3.630USD

-0.040-1.09%

Close 05/08, 16:00（ET）Quotes delayed by 15 min

Rocket Pharmaceuticals Inc's Score

Industry at a Glance

Industry Ranking

174 / 384

Overall Ranking

338 / 4494

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Negative

Rocket Pharmaceuticals Inc Highlights

StrengthsRisks

Rocket Pharmaceuticals, Inc. is a fully integrated, late-stage biotechnology company focused on the development of gene therapies for rare and devastating diseases. The Company has two clinical stage and one pre-clinical stage in vivo adeno-associated viral (AAV) programs in the United States, which include programs for Danon disease (DD), a multi-organ lysosomal-associated disorder leading to early death due to heart failure; Plakophilin-2 Arrhythmogenic Cardiomyopathy (PKP2-ACM), an inheritable cardiac disorder that is characterized by a progressive loss of cardiac muscle mass, severe right ventricular dilation, dysplasia, fibrofatty replacement of the myocardium and a high propensity to arrhythmias and sudden death (RP-A601), and BAG3 Dilated Cardiomyopathy (BAG3-DCM), which is the most common form of cardiomyopathy and is characterized by progressive thinning of the walls of the heart resulting in enlarged heart chambers that are unable to pump blood.

Overvalued

The company’s latest PE is -1.94, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 97.32M shares, decreasing 24.79% quarter-over-quarter.

Held by Invesco

Star Investor Invesco holds 276.91K shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 1.90.

Analyst Rating

Based on 14 analysts

Hold

Current Rating

9.295

Target Price

+153.28%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current financial score of Rocket Pharmaceuticals Inc is 5.45, ranking 357 out of 384 in the Biotechnology & Medical Research industry. Its financial status is weak, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

5.45

Change

0



Financials

2.04

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.43

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

4.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

6.75

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.03

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

The current valuation score of Rocket Pharmaceuticals Inc is 7.73, ranking 82 out of 384 in the Biotechnology & Medical Research industry. Its current P/E ratio is -1.94, which is -54.11% below the recent high of -0.89 and -443.19% above the recent low of -10.52.

Score

Industry at a Glance

Previous score

7.73

Change

0

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 174/384

Relevant data have not been disclosed by the company yet.

The current earnings forecast score of Rocket Pharmaceuticals Inc is 6.86, ranking 324 out of 384 in the Biotechnology & Medical Research industry. The average price target is 8.00, with a high of 16.00 and a low of 2.00.

Score

Industry at a Glance

Previous score

6.86

Change

0

Support & Resistance

Relevant data have not been disclosed by the company yet.

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current price momentum score of Rocket Pharmaceuticals Inc is 4.26, ranking 346 out of 384 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 4.05 and the support level at 3.26, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

4.32

Change

-0.06

Support & Resistance

Relevant data have not been disclosed by the company yet.

Institutional Confidence

Currency: USD Updated: 2026-05-08

The current institutional shareholding score of Rocket Pharmaceuticals Inc is 7.00, ranking 79 out of 384 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 89.20%, representing a quarter-over-quarter decrease of 2.95%. The largest institutional shareholder is The Vanguard, holding a total of 8.51M shares, representing 7.80% of shares outstanding, with 27.29% increase in holdings.

Score

Industry at a Glance

Previous score

7.00

Change

0

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

RTW Investments L.P.

17.69M

--

BlackRock Institutional Trust Company, N.A.

6.50M

+7.90%

Citi Investment Research (US)

5.25M

+50224.69%

Two Sigma Investments, LP

4.01M

+17.71%

Suvretta Capital Management, LLC

2.99M

-22.13%

Monaco asset management S.A.M.

2.99M

+3.29%

Morgan Stanley & Co. LLC

2.84M

+6.52%



1

2



The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. No risk assessment score is currently available for Rocket Pharmaceuticals Inc. The Biotechnology & Medical Research industry's average is 3.36. The company's beta value is 0.51. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.

Rocket Pharmaceuticals Inc

RCKT

5.45 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

IQVIA Holdings Inc

IQV

8.76 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Krystal Biotech Inc

KRYS

8.61 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Ascendis Pharma A/S

ASND

8.45 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Exelixis Inc

EXEL

8.44 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

AnaptysBio Inc

ANAB

8.43 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment